Wen Li1, David C Newitt1, Lisa J Wilmes1, Ella F Jones1, Vignesh Arasu1, Jessica Gibbs1, Bo La Yun1,2, Elizabeth Li1,3, Savannah C Partridge4, John Kornak5, Laura J Esserman6, Nola M Hylton1. 1. Department of Radiology & Biomedical Imaging, University of California, San Francisco, California, USA. 2. Department of Radiology, Seoul National University Bundang Hospital, Seoul, Korea. 3. Department of Biomedical Engineering, University of California, Davis, California, USA. 4. Department of Radiology, University of Washington, Seattle, Washington, USA. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA. 6. Department of Surgery, University of California, San Francisco, California, USA.
Abstract
BACKGROUND: The change in apparent diffusion coefficient (ADC) measured from diffusion-weighted imaging (DWI) has been shown to be predictive of pathologic complete response (pCR) for patients with locally invasive breast cancer undergoing neoadjuvant chemotherapy. PURPOSE: To investigate the additive value of tumor ADC in a multicenter clinical trial setting. STUDY TYPE: Retrospective analysis of multicenter prospective data. POPULATION: In all, 415 patients who enrolled in the I-SPY 2 TRIAL from 2010 to 2014 were included. FIELD STRENGTH/SEQUENCE: 1.5T or 3T MRI system using a fat-suppressed single-shot echo planar imaging sequence with b-values of 0 and 800 s/mm2 for DWI, followed by a T1-weighted sequence for dynamic contrast-enhanced MRI (DCE-MRI) performed at pre-NAC (T0), after 3 weeks of NAC (T1), mid-NAC (T2), and post-NAC (T3). ASSESSMENT: Functional tumor volume and tumor ADC were measured at each MRI exam; pCR measured at surgery was assessed as the binary outcome. Breast cancer subtype was defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. STATISTICAL TESTS: A logistic regression model was used to evaluate associations between MRI predictors with pCR. The cross-validated area under the curve (AUC) was calculated to assess the predictive performance of the model with and without ADC. RESULTS: In all, 354 patients (128 HR+/HER2-, 60 HR+/HER2+, 34 HR-/HER2+, 132 HR-/HER2-) were included in the analysis. In the full cohort, adding ADC predictors increased the AUC from 0.76 to 0.78 at mid-NAC and from 0.76 to 0.81 at post-NAC. In HR/HER2 subtypes, the AUC increased from 0.52 to 0.65 at pre-NAC for HR+/HER2-, from 0.67 to 0.73 at mid-NAC and from 0.72 to 0.76 at post-NAC for HR+/HER2+, from 0.71 to 0.81 at post-NAC for triple negatives. DATA CONCLUSION: The addition of ADC to standard functional tumor volume MRI showed improvement in the prediction of treatment response in HR+ and triple-negative breast cancer. LEVEL OF EVIDENCE: 2 Technical Efficacy Stage: 4 J. Magn. Reson. Imaging 2019;50:1742-1753.
RCT Entities:
BACKGROUND: The change in apparent diffusion coefficient (ADC) measured from diffusion-weighted imaging (DWI) has been shown to be predictive of pathologic complete response (pCR) for patients with locally invasive breast cancer undergoing neoadjuvant chemotherapy. PURPOSE: To investigate the additive value of tumorADC in a multicenter clinical trial setting. STUDY TYPE: Retrospective analysis of multicenter prospective data. POPULATION: In all, 415 patients who enrolled in the I-SPY 2 TRIAL from 2010 to 2014 were included. FIELD STRENGTH/SEQUENCE: 1.5T or 3T MRI system using a fat-suppressed single-shot echo planar imaging sequence with b-values of 0 and 800 s/mm2 for DWI, followed by a T1-weighted sequence for dynamic contrast-enhanced MRI (DCE-MRI) performed at pre-NAC (T0), after 3 weeks of NAC (T1), mid-NAC (T2), and post-NAC (T3). ASSESSMENT: Functional tumor volume and tumorADC were measured at each MRI exam; pCR measured at surgery was assessed as the binary outcome. Breast cancer subtype was defined by hormone receptor (HR) and humanepidermal growth factor receptor 2 (HER2) status. STATISTICAL TESTS: A logistic regression model was used to evaluate associations between MRI predictors with pCR. The cross-validated area under the curve (AUC) was calculated to assess the predictive performance of the model with and without ADC. RESULTS: In all, 354 patients (128 HR+/HER2-, 60 HR+/HER2+, 34 HR-/HER2+, 132 HR-/HER2-) were included in the analysis. In the full cohort, adding ADC predictors increased the AUC from 0.76 to 0.78 at mid-NAC and from 0.76 to 0.81 at post-NAC. In HR/HER2 subtypes, the AUC increased from 0.52 to 0.65 at pre-NAC for HR+/HER2-, from 0.67 to 0.73 at mid-NAC and from 0.72 to 0.76 at post-NAC for HR+/HER2+, from 0.71 to 0.81 at post-NAC for triple negatives. DATA CONCLUSION: The addition of ADC to standard functional tumor volume MRI showed improvement in the prediction of treatment response in HR+ and triple-negative breast cancer. LEVEL OF EVIDENCE: 2 Technical Efficacy Stage: 4 J. Magn. Reson. Imaging 2019;50:1742-1753.
Authors: Nehmat Houssami; Petra Macaskill; Gunter von Minckwitz; Michael L Marinovich; Eleftherios Mamounas Journal: Eur J Cancer Date: 2012-07-03 Impact factor: 9.162
Authors: David C Newitt; Sheye O Aliu; Neil Witcomb; Gal Sela; John Kornak; Laura Esserman; Nola M Hylton Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: Xia Li; Lori R Arlinghaus; Gregory D Ayers; A Bapsi Chakravarthy; Richard G Abramson; Vandana G Abramson; Nkiruka Atuegwu; Jaime Farley; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie Means-Powell; Ana M Grau; Melinda Sanders; Sandeep R Bhave; Thomas E Yankeelov Journal: Magn Reson Med Date: 2013-05-09 Impact factor: 4.668
Authors: Laura J Esserman; Donald A Berry; Maggie C U Cheang; Christina Yau; Charles M Perou; Lisa Carey; Angela DeMichele; Joe W Gray; Kathleen Conway-Dorsey; Marc E Lenburg; Meredith B Buxton; Sarah E Davis; Laura J van't Veer; Clifford Hudis; Koei Chin; Denise Wolf; Helen Krontiras; Leslie Montgomery; Debu Tripathy; Constance Lehman; Minetta C Liu; Olufunmilayo I Olopade; Hope S Rugo; John T Carpenter; Chad Livasy; Lynn Dressler; David Chhieng; Baljit Singh; Carolyn Mies; Joseph Rabban; Yunni-Yi Chen; Dilip Giri; Alfred Au; Nola Hylton Journal: Breast Cancer Res Treat Date: 2011-12-25 Impact factor: 4.872
Authors: Savannah C Partridge; Zheng Zhang; David C Newitt; Jessica E Gibbs; Thomas L Chenevert; Mark A Rosen; Patrick J Bolan; Helga S Marques; Justin Romanoff; Lisa Cimino; Bonnie N Joe; Heidi R Umphrey; Haydee Ojeda-Fournier; Basak Dogan; Karen Oh; Hiroyuki Abe; Jennifer S Drukteinis; Laura J Esserman; Nola M Hylton Journal: Radiology Date: 2018-09-04 Impact factor: 29.146
Authors: David C Newitt; Dariya Malyarenko; Thomas L Chenevert; C Chad Quarles; Laura Bell; Andriy Fedorov; Fiona Fennessy; Michael A Jacobs; Meiyappan Solaiyappan; Stefanie Hectors; Bachir Taouli; Mark Muzi; Paul E Kinahan; Kathleen M Schmainda; Melissa A Prah; Erin N Taber; Christopher Kroenke; Wei Huang; Lori R Arlinghaus; Thomas E Yankeelov; Yue Cao; Madhava Aryal; Yi-Fen Yen; Jayashree Kalpathy-Cramer; Amita Shukla-Dave; Maggie Fung; Jiachao Liang; Michael Boss; Nola Hylton Journal: J Med Imaging (Bellingham) Date: 2017-10-10
Authors: Chengyue Wu; Angela M Jarrett; Zijian Zhou; Nabil Elshafeey; Beatriz E Adrada; Rosalind P Candelaria; Rania M M Mohamed; Medine Boge; Lei Huo; Jason B White; Debu Tripathy; Vicente Valero; Jennifer K Litton; Clinton Yam; Jong Bum Son; Jingfei Ma; Gaiane M Rauch; Thomas E Yankeelov Journal: Cancer Res Date: 2022-09-16 Impact factor: 13.312
Authors: M J M Magbanua; L B Swigart; H-T Wu; G L Hirst; C Yau; D M Wolf; A Tin; R Salari; S Shchegrova; H Pawar; A L Delson; A DeMichele; M C Liu; A J Chien; D Tripathy; S Asare; C-H J Lin; P Billings; A Aleshin; H Sethi; M Louie; B Zimmermann; L J Esserman; L J van 't Veer Journal: Ann Oncol Date: 2020-11-21 Impact factor: 51.769
Authors: Mark Jesus M Magbanua; Wen Li; Denise M Wolf; Christina Yau; Gillian L Hirst; Lamorna Brown Swigart; David C Newitt; Jessica Gibbs; Amy L Delson; Ekaterina Kalashnikova; Alexey Aleshin; Bernhard Zimmermann; A Jo Chien; Debu Tripathy; Laura Esserman; Nola Hylton; Laura van 't Veer Journal: NPJ Breast Cancer Date: 2021-03-25
Authors: Liselore M Janssen; Britt B M Suelmann; Sjoerd G Elias; Markus H A Janse; Paul J van Diest; Elsken van der Wall; Kenneth G A Gilhuijs Journal: BMJ Open Date: 2022-09-20 Impact factor: 3.006
Authors: Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton Journal: Cancers (Basel) Date: 2020-06-09 Impact factor: 6.575
Authors: Wen Li; David C Newitt; Jessica Gibbs; Lisa J Wilmes; Ella F Jones; Vignesh A Arasu; Fredrik Strand; Natsuko Onishi; Alex Anh-Tu Nguyen; John Kornak; Bonnie N Joe; Elissa R Price; Haydee Ojeda-Fournier; Mohammad Eghtedari; Kathryn W Zamora; Stefanie A Woodard; Heidi Umphrey; Wanda Bernreuter; Michael Nelson; An Ly Church; Patrick Bolan; Theresa Kuritza; Kathleen Ward; Kevin Morley; Dulcy Wolverton; Kelly Fountain; Dan Lopez-Paniagua; Lara Hardesty; Kathy Brandt; Elizabeth S McDonald; Mark Rosen; Despina Kontos; Hiroyuki Abe; Deepa Sheth; Erin P Crane; Charlotte Dillis; Pulin Sheth; Linda Hovanessian-Larsen; Dae Hee Bang; Bruce Porter; Karen Y Oh; Neda Jafarian; Alina Tudorica; Bethany L Niell; Jennifer Drukteinis; Mary S Newell; Michael A Cohen; Marina Giurescu; Elise Berman; Constance Lehman; Savannah C Partridge; Kimberly A Fitzpatrick; Marisa H Borders; Wei T Yang; Basak Dogan; Sally Goudreau; Thomas Chenevert; Christina Yau; Angela DeMichele; Don Berry; Laura J Esserman; Nola M Hylton Journal: NPJ Breast Cancer Date: 2020-11-27